Taysha Gene Therapies, Inc.: shareholders and insiders

TSHANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$3.72

November 20, 2026Market cap $1.2B

What Ploutos Investor adds for Taysha Gene Therapies

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Jul 10, 2026, from their own Form 4 filings.

5 Form 4s

Bought on the market

–

nobody

Sold on the market

$6.7M

3 people

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan46%
  • The rest54%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $5.0M by 3 people

  • 2025: no buys, sold $1.7M by 1 person
  • 2026: no buys, sold $5.0M by 3 people
  • Jul 10, 2026Sukumar NagendranPresident and Head of R&D
    Kind10b5-1
  • Jun 1, 2026John A Stalfort IIIDirector
    Kind
  • Jun 1, 2026Phillip B. DonenbergDirector
    Kind
  • Jun 1, 2026Alison S LongDirector
    Kind
  • Jun 1, 2026Laura Sepp-LorenzinoDirector
    Kind
  • Apr 10, 2026Sukumar NagendranPresident and Head of R&D
    Kind10b5-1
  • Feb 4, 2026Kamran AlamCHIEF FINANCIAL OFFICER
    Kind
  • Jan 26, 2026Sean P. NolanChief Executive Officer
    Kind
  • Jan 26, 2026Sukumar NagendranPresident and Head of R&D
    Kind
  • Jan 26, 2026Kamran AlamCHIEF FINANCIAL OFFICER
    Kind
  • Jan 23, 2026Sean P. NolanChief Executive Officer
    Kind
  • Jan 23, 2026Sukumar NagendranPresident and Head of R&D
    Kind
  • Jan 23, 2026Kamran AlamCHIEF FINANCIAL OFFICER
    Kind
  • Jan 12, 2026Sukumar NagendranPresident and Head of R&D
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by TSHA's officers and directors from 2021 up to November 21, 2025, 5 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

7 Holders over 5%1 On a 13DAug 14, 2026 Latest filing
  • RA Capital Management, L.P.with 3 more persons
    Share of class9.90%
  • Paul B Manningwith 5 more persons
    Share of class9.80%
  • RTW Investments, LPwith 1 more person
    Share of class7.00%
  • BlackRock, Inc.
    Share of class6.50%
  • Vestal Point Capital, LPwith 1 more person
    Share of class6.30%
  • Morgan Stanleywith 1 more person
    Share of class5.10%
  • The Goldman Sachs Groupwith 1 more person
    Share of class5.10%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • FMR4.90%Feb 5, 202613G/A
  • Octagon Capital Advisors LP3.30%Nov 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • D.E. Shaw
    In the quarter+37%
  • Citadel Advisors (Griffin)
    In the quarter+114%
  • Millennium Mgmt (Englander)
    In the quarter-6.1%
  • AQR Capital
    In the quarter+7.4%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 15.7% of its shares outstanding were held short, -6.9% since the report before.

Shares held short
51.25M
15.7%
Since the report before55.02M on Sep 30, 2026
-6.9%
11.6
4.43M
More days to cover thanof 4,578 US-listed companies with enough volume
95%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 9.76M
  • Nov 15, 2023: Shares held short 13.95M
  • Nov 30, 2023: Shares held short 16.16M
  • Dec 15, 2023: Shares held short 17.13M
  • Dec 29, 2023: Shares held short 17.53M
  • Jan 12, 2024: Shares held short 17.49M
  • Jan 31, 2024: Shares held short 16.78M
  • Feb 15, 2024: Shares held short 16.30M
  • Feb 29, 2024: Shares held short 13.88M
  • Mar 15, 2024: Shares held short 15.81M
  • Mar 28, 2024: Shares held short 16.99M
  • Apr 15, 2024: Shares held short 16.07M
  • Apr 30, 2024: Shares held short 16.91M
  • May 15, 2024: Shares held short 17.04M
  • May 31, 2024: Shares held short 16.12M
  • Jun 14, 2024: Shares held short 14.72M
  • Jun 28, 2024: Shares held short 13.45M
  • Jul 15, 2024: Shares held short 20.81M
  • Jul 31, 2024: Shares held short 23.21M
  • Aug 15, 2024: Shares held short 20.78M
  • Aug 30, 2024: Shares held short 21.66M
  • Sep 13, 2024: Shares held short 19.83M
  • Sep 30, 2024: Shares held short 20.64M
  • Oct 15, 2024: Shares held short 20.70M
  • Oct 31, 2024: Shares held short 17.64M
  • Nov 15, 2024: Shares held short 15.75M
  • Nov 29, 2024: Shares held short 15.67M
  • Dec 13, 2024: Shares held short 21.88M
  • Dec 31, 2024: Shares held short 25.88M
  • Jan 15, 2025: Shares held short 23.95M
  • Jan 31, 2025: Shares held short 24.08M
  • Feb 14, 2025: Shares held short 25.09M
  • Feb 28, 2025: Shares held short 25.53M
  • Mar 14, 2025: Shares held short 25.25M
  • Mar 31, 2025: Shares held short 21.63M
  • Apr 15, 2025: Shares held short 23.15M
  • Apr 30, 2025: Shares held short 26.06M
  • May 15, 2025: Shares held short 26.24M
  • May 30, 2025: Shares held short 31.98M
  • Jun 13, 2025: Shares held short 33.27M
  • Jun 30, 2025: Shares held short 39.85M
  • Jul 15, 2025: Shares held short 43.96M
  • Jul 31, 2025: Shares held short 38.21M
  • Aug 15, 2025: Shares held short 36.41M
  • Aug 29, 2025: Shares held short 40.78M
  • Sep 15, 2025: Shares held short 43.36M
  • Sep 30, 2025: Shares held short 49.55M
  • Oct 15, 2025: Shares held short 41.98M
  • Oct 31, 2025: Shares held short 44.37M
  • Nov 14, 2025: Shares held short 48.08M
  • Nov 28, 2025: Shares held short 49.04M
  • Dec 15, 2025: Shares held short 48.59M
  • Dec 31, 2025: Shares held short 56.03M
  • Jan 15, 2026: Shares held short 56.85M
  • Jan 30, 2026: Shares held short 55.69M
  • Feb 13, 2026: Shares held short 48.96M
  • Feb 27, 2026: Shares held short 49.69M
  • Mar 13, 2026: Shares held short 46.39M
  • Mar 31, 2026: Shares held short 42.27M
  • Apr 15, 2026: Shares held short 38.92M
  • Apr 30, 2026: Shares held short 40.05M
  • May 15, 2026: Shares held short 36.70M
  • May 29, 2026: Shares held short 36.01M
  • Jun 15, 2026: Shares held short 38.73M
  • Jun 30, 2026: Shares held short 41.40M
  • Jul 15, 2026: Shares held short 45.29M
  • Jul 31, 2026: Shares held short 46.69M
  • Aug 14, 2026: Shares held short 46.74M
  • Aug 31, 2026: Shares held short 46.80M
  • Sep 15, 2026: Shares held short 51.41M
  • Sep 30, 2026: Shares held short 55.02M
  • Oct 15, 2026: Shares held short 51.25M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading58.0% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 58.0% of the shares in the reported trades were short sales, against 61.5% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
58.0%
The 14 beforeOct 14, 2026 – Nov 2, 2026
61.5%
Change
-3.5 pts
Short sales a dayon average, of 1.14M shares
659.2K
More than atof 3,666 US-listed companies, same days
77%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 40.6%
  • Oct 15, 2026: Short sales 57%
  • Oct 16, 2026: Short sales 73.4%
  • Oct 19, 2026: Short sales 69.6%
  • Oct 20, 2026: Short sales 50.8%
  • Oct 21, 2026: Short sales 49.1%
  • Oct 22, 2026: Short sales 55.2%
  • Oct 23, 2026: Short sales 64.5%
  • Oct 26, 2026: Short sales 66.1%
  • Oct 27, 2026: Short sales 75.1%
  • Oct 28, 2026: Short sales 89%
  • Oct 29, 2026: Short sales 60.5%
  • Oct 30, 2026: Short sales 63%
  • Nov 2, 2026: Short sales 75.5%
  • Nov 3, 2026: Short sales 54.9%
  • Nov 4, 2026: Short sales 62%
  • Nov 5, 2026: Short sales 60.6%
  • Nov 6, 2026: Short sales 76.5%
  • Nov 9, 2026: Short sales 82.8%
  • Nov 10, 2026: Short sales 49.7%
  • Nov 11, 2026: Short sales 59.2%
  • Nov 12, 2026: Short sales 48.6%
  • Nov 13, 2026: Short sales 53.8%
  • Nov 16, 2026: Short sales 44.9%
  • Nov 17, 2026: Short sales 44.9%
  • Nov 18, 2026: Short sales 34.1%
  • Nov 19, 2026: Short sales 36.2%
  • Nov 20, 2026: Short sales 73.8%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

12.02M Insiders' shares4.18% Of the company
  • Paul B ManningTenPercentOwner
    Directly1.33M
  • Sean P. NolanChief Executive Officer
    Directly2.91M
  • John A Stalfort IIIDirector
    Directly2.06M
  • Kamran AlamCHIEF FINANCIAL OFFICER
    Directly1.44M
  • Sukumar NagendranPresident and Head of R&D
    Directly936.4K
  • Phillip B. DonenbergDirector
    Directly241.3K
  • Alison S LongDirector
    Directly127.2K
  • Laura Sepp-LorenzinoDirector
    Directly127.2K

A lower bound: it counts only the 8 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

19 ETFs holding it0.35% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.35%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.22%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.13%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.10%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.10%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.05%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.04%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.03%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.02%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%

19 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

209 Managers, Q2 2026$2.1B Value of their positions
  • Q3 2025: Managers 155
  • Q4 2025: Managers 195
  • Q1 2026: Managers 193
  • Q2 2026: Managers 209

Institutional investors by quarter

The fund managers holding TSHA, quarter by quarter, from Q3 2020 to Q2 2025, 20 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 209 managers held 300M shares, worth $2.1B. During the quarter 41 opened a position, 25 closed one, 96 added and 41 trimmed.

The largest holders, Q2 2026

  • Avoro Capital Advisors
    In the quarter+10%
  • Ra Capital Management
    In the quarter
  • Goldman Sachs Group
    In the quarter+1.5%
  • BlackRock
    In the quarter+13%
  • Vestal Point Capital
    In the quarter+7.9%
  • Morgan Stanley
    In the quarter-8.2%
  • Rtw Investments
    In the quarter-0.9%
  • FMR
    In the quarter-6.9%
  • Vanguard Capital Management
    In the quarter+22%
  • State Street
    In the quarter+1.9%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Taysha Gene Therapies's filings show?

Who buys and sells is one part of Taysha Gene Therapies's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about TSHA's shareholders

Didn't find what you were looking for?

Ask us
Have TSHA's insiders bought or sold?

From Jun 2, 2026 to Jul 10, 2026 Taysha Gene Therapies's insiders bought 0 and sold $1.2M of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold TSHA?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $29M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.